Ibogamine

Ibogamine

Ibogamine
Systematic (IUPAC) name
[6R-(6α,6aβ,7β,9α)]-7-ethyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole
Clinical data
Legal status
?
Identifiers
CAS number  N
ATC code None
PubChem
ChemSpider  YesY
ChEBI  YesY
Chemical data
Formula C19H24N2 
Mol. mass 280.41 g/mol
 N   

Ibogamine is an [2]

Basic research related to how addiction affects the brain has used this chemical.[3]

Ibogamine reduced the self-administration of cocaine and morphine in rats more consistently than other iboga alkaloids, even ibogaine.[4]

See also

References

  1. ^ Bartlett, M. F.; Dickel, D. F.; Taylor, W. I. (1958). "The Alkaloids of Tabernanthe iboga. Part IV.1 The Structures of Ibogamine, Ibogaine, Tabernanthine and Voacangine - Journal of the American Chemical Society (ACS Publications)". Journal of the American Chemical Society 80 (1): 126.  
  2. ^ Kuehne, Martin E.; Reider, Paul J. (1985). "A synthesis of ibogamine - The Journal of Organic Chemistry (ACS Publications)". The Journal of Organic Chemistry 50 (9): 1464.  
  3. ^ Levi MS, Borne RF (October 2002). "A review of chemical agents in the pharmacotherapy of addiction". Curr. Med. Chem. 9 (20): 1807–18.  
  4. ^ Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr, Carlson JN (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.". Brain Res. 657 (1-2): 14–22.